CN1535686A - Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method - Google Patents
Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method Download PDFInfo
- Publication number
- CN1535686A CN1535686A CNA031094023A CN03109402A CN1535686A CN 1535686 A CN1535686 A CN 1535686A CN A031094023 A CNA031094023 A CN A031094023A CN 03109402 A CN03109402 A CN 03109402A CN 1535686 A CN1535686 A CN 1535686A
- Authority
- CN
- China
- Prior art keywords
- loratadine
- sheet
- pseudoephedrine sulfate
- slow
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KBYGOCNIUHCOLP-MNIONDOCSA-N ethyl 4-(8-chloro-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridin-11-ylidene)piperidine-1-carboxylate;(1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 KBYGOCNIUHCOLP-MNIONDOCSA-N 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 238000000576 coating method Methods 0.000 claims abstract description 11
- 229960003088 loratadine Drugs 0.000 claims abstract description 11
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims abstract description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 claims description 16
- 229960004159 pseudoephedrine sulfate Drugs 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 11
- 239000004816 latex Substances 0.000 claims description 7
- 229920000126 latex Polymers 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229940049654 glyceryl behenate Drugs 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 229960003943 hypromellose Drugs 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 229940080781 loratadine 5 mg Drugs 0.000 claims description 4
- 229940103212 pseudoephedrine 60 mg Drugs 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 239000007891 compressed tablet Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract description 2
- 230000006835 compression Effects 0.000 abstract 2
- 238000007906 compression Methods 0.000 abstract 2
- 206010028748 Nasal obstruction Diseases 0.000 abstract 1
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 abstract 1
- 229960004842 ephedrine sulfate Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229940080780 loratadine 10 mg Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940022361 pseudoephedrine sulfate 120 mg Drugs 0.000 description 1
- 229940022342 pseudoephedrine sulfate 240 mg Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a slowly-released preparation containing loratadine and ephedrine sulfate and its preparation method. It adopts compression coating method to compress the slowly-releasing external layer on the exterior of slowly-releasing tablet core to obtain the invented compression-coated slowly-released tablet mainly for clinically-relieving rhinallergosis and nasal obstruction due to common cold.
Description
Technical field
The invention relates to a kind of new prescription composition and preparation method of slow releasing tablet that is used to alleviate allergic rhinitis and cold symptoms clinically.
Loratadine is a kind of long lasting tricyclic antidepressants antihistamine drug, clinical showing, its selectively acting is in the periphery histamine H1-receptor, no central nervous system's inhibitory action, therefore the antihistaminic that belongs to no drowsiness effect was taken once and then can effectively be alleviated allergic rhinitis in one day; Pseudoephedrine sulfate is traditional sympathomimetic amine, takes four times in one day, can effectively suppress nasal mucosa hyperemia.Both effectively combine, make and took twice slow releasing preparation in one day, can bring into play the antihistamine effect of loratadine and the dual function that alleviates nasal congestion of pseudoephedrine sulfate simultaneously, the related symptoms that also permanent rapidly alleviation allergic rhinitis and flu cause, few side effects, and taking convenience.
Background technology
The development and production of Schering Plough pharmaceutical Co. Ltd the product of commodity CLARITIN-D by name, CLARITIN-D 12HOUR and two kinds of specifications of CLARITIN-D 24 HOUR are arranged, obtain import drugs in China in 1999 and produce certification (CLARITIN-D 12HOUR), by the packing listing of Shanghai Schering Plough pharmaceutical Co. Ltd, commodity are called Clarinase, its specification is loratadine 5mg, pseudoephedrine sulfate 120mg, form by label and coatings two parts, coatings is an immediate release section, sulfur acid pseudoephedrine 60mg, loratadine 5mg, discharge the performance drug effect after taking medicine immediately, and kept 6 hours; Label is a slow-released part, and sulfur acid pseudoephedrine 60mg can begin to disengage taking medicine in back 6 hours, continue to keep back 6 hours drug effect, and loratadine itself is exactly the long-acting type medicine, can 12 hours effective relief of symptoms after taking.
Schering Corp China and U. S. application the patent of CLARITIN-D 24 HOUR, the patent No. is respectively 93,118, and 769 and 5,314,697, specification is pseudoephedrine sulfate 240mg, loratadine 10mg, pseudoephedrine sulfate is a slow-released part, in the matrix type label, loratadine is an immediate release section, adopts the coating mode to be wrapped in outside the label.
The main adjuvant of CLARITIN-D 12 HOUR has that lactose, starch, polyvinylpyrrolidone, arabic gum, microcrystalline Cellulose, sucrose, calcium sulfate, white beeswax, babassu are cured, Pulvis Talci and magnesium stearate etc.Its label is surrounded by wax material outward, delays the release of medicine; Immediate release drug is in coatings, and outermost layer is a sugarcoating layer.
Because the pseudoephedrine sulfate specification is bigger in the skin, and the loratadine specification is 5mg, by the coating wayward uniformity of dosage units of adding medicine to, and sugar coating length consuming time, production efficiency is low.
Goal of the invention
Because the coating sheeting equipment of external existing molding, domestic also have producer successfully to copy this pressed coated equipment, and we study adjustment to prescription, adopts the method for pressed coated to prepare slow releasing tablet.Adopt pressed coated technology, not only can solve the gentle problem of releasing of rapid release in the preparation, and can better solve the uniformity problem of clothing layer Chinese medicine, enhance productivity.
Detailed Description Of The Invention
The commodity that we produce with reference to Schering-Plough company are called the specification of CLARITIN-D 12 HOUR, and prescription is adjusted, and adopt the method for pressed coated to prepare slow releasing tablet, and the sheet core segment is a slow-released part, sulfur acid pseudoephedrine 60mg; Compacting clothing layer segment is immediate release section, contains loratadine 5mg, pseudoephedrine sulfate 60mg.
Adopting polymethylacrylic acid latex (gastric disintegrable type, 30%) is binding agent, is easy to granulate; Glyceryl Behenate plays the retardance slow releasing function; Hypromellose E50-LV regulates the outer field release of slow releasing tablet, improves slice, thin piece hardness simultaneously; Sucrose plays the bonding agent effect; Calcium sulfate, lactose are filler; Magnesium stearate is a lubricant.
1. prescription is formed:
(1) immediate release section is outer forms:
The mg/ sheet
Loratadine 5
Pseudoephedrine sulfate 60
Hypromellose E50-LV 75
Sucrose 15
Lactose 137
Magnesium stearate 3
(2) the slow-released part label is formed:
The mg/ sheet
Pseudoephedrine sulfate 60
Glyceryl Behenate 140
Calcium sulfate 20
Latex liquid of polymethacrylic resin (30%) 10
Magnesium stearate 2
(3) slow releasing tablet is formed:
The mg/ sheet
Slow-released part label 232
Immediate release section skin 295
2. preparation technology:
(1) sheet core segment: in the prescription ratio, with principal agent and adjuvant pulverize, sieve, behind the mixing, with latex liquid of polymethacrylic resin system soft material, the granulation of sieving, oven dry back add the magnesium stearate mixing, and be standby.
(2) preparation of coatings part is with the sheet core segment.Principal agent and adjuvant are sieved, behind the mixing, granulate with 60% alcoholic solution, and the oven dry back adds the magnesium stearate mixing, and is standby.
(3) adopt the pressed coated machine to carry out tabletting, label 232mg, outer 295mg, the heavy 527mg of theoretical sheet.
Embodiment
1. prescription is formed
(1) the outer layer segment of rapid release is formed:
The mg/ sheet
Loratadine 5
Pseudoephedrine sulfate 60
Hypromellose E50-LV 85
Sucrose 16
Lactose 132
Magnesium stearate 2
(2) the slow releasing tablet core segment is formed:
The mg/ sheet
Pseudoephedrine sulfate 60
Glyceryl Behenate 130
Calcium sulfate 30
Latex liquid of polymethacrylic resin (30%) 12
Magnesium stearate 3
(3) slow releasing tablet is formed:
The mg/ sheet
Slow releasing tablet core segment 235
The outer layer segment 300 of rapid release
2. preparation technology:
(1) sheet core segment: in the prescription ratio, with principal agent and adjuvant pulverize, sieve, behind the mixing, with latex liquid of polymethacrylic resin system soft material, the granulation of sieving, oven dry back add the magnesium stearate mixing, with 8mm scrobicula punching press film-making core.
(2) preparation of pressed coated layer segment is with the sheet core segment.Principal agent and adjuvant are sieved, behind the mixing, granulate with 60% alcoholic solution, and the oven dry back adds the magnesium stearate mixing, and is standby.
(3) pressed coated: adopt pressed coated machine 11mm scrobicula punching press system coating.Label 235mg, outer 300mg, the heavy 535mg of theoretical sheet.
3. drug release determination
Slow releasing tablet with reference to above-mentioned prepared, according to drug release determination method (two appendix XD first methods of Chinese Pharmacopoeia version in 2000), adopt dissolution method (two appendix XC first methods of Chinese Pharmacopoeia version in 2000) device, with 0.01mol/L hydrochloric acid solution 900ml is solvent, rotating speed is that per minute 100 changes, sampling and measuring, release is table 1 as a result, and 2.The result shows, self-control slow releasing tablet and comparison film release behavior basically identical.
Table 1 pseudoephedrine sulfate drug release determination result (%)
Time
Sample 123456 average ± SD
(hour)
0.5 45.8 43.3 44.0 45.1 42.4 46.9 44.6±1.67
1 47.6 49.0 50.9 50.0 47.9 48.4 49.0±1.25
2 50.4 52.2 56.2 56.9 51.2 50.8 52.9±2.85
From
4 58.0 64.2 64.3 64.6 63.9 58.7 62.3±3.06
System
6 68.8 79.4 77.0 77.3 79.1 67.5 74.9±5.28
Sheet
8 79.4 89.7 88.3 89.1 90.2 76.8 85.6±5.89
10 88.3 94.3 93.5 94.4 95.6 85.0 91.9±4.21
12 89.5 94.3 95.1 94.6 93.4 89.1 92.7±2.67
0.5 51.4 53.7 43.5 46.8 48.1 45.1 48.1±3.88
1 53.1 53.8 46.7 51.0 50.0 51.2 51.0±2.53
2 52.7 52.5 46.2 48.9 51.1 51.6 50.5±2.51
Right
4 55.1 56.9 48.9 55.8 53.8 52.6 53.8±2.85
According to
6 72.7 59.6 69.6 70.6 64.4 61.9 66.5±5.26
Sheet
8 93.4 82.0 90.4 93.3 80.9 80.8 86.8±6.20
10 97.2 94.1 96.6 98.3 90.8 95.1 95.4±2.70
12 101.1 105.4 96.6 101.8 101.7 100.3 101.1±2.83
Remarks: comparison film is Clarinase , by the packing of Shanghai Schering Plough pharmaceutical Co. Ltd.Lot number: 01CJRPD002
Table 2 loratadine drug release determination result (%)
Time
Sample 123456 average ± SD
(little
The time)
0.5 71.3 68.2 75.6 75.2 69.3 72.4 72.0±2.99
1 92.0 95.0 97.6 98.6 95.6 93.3 95.3±2.49
2 95.1 97.6 100.0 100.5 98.3 95.7 97.9±2.20
From
4 96.2 95.8 98.8 99.9 96.9 96.0 97.3±1.71
System
6 95.4 96.7 97.3 99.0 97.3 96.4 97.0±1.19
Sheet
8 93.7 94.3 95.4 96.7 96.1 94.9 95.2±1.14
10 93.1 98.2 97.4 98.1 98.6 93.8 96.5±2.43
12 95.1 93.9 98.1 99.1 95.5 95.9 96.3±1.95
0.5 85.7 89.6 84.3 83.7 85.1 72.0 83.4±5.96
1 96.3 98.6 92.8 97.0 92.0 82.5 93.2±5.83
To 2 93.4 95.5 94.3 96.9 93.5 97.0 95.1 ± 1.62
According to 4 99.8 99.5 95.6 96.9 93.5 98.0 97.2 ± 2.43
Sheet 6 99.5 98.8 99.0 98.0 94.6 97.2 97.8 ± 1.79
8 100.8 99.6 99.5 98.9 94.6 96.3 98.3±2.35
10 100.2 99.7 99.5 100.2 95.0 97.4 98.7±2.06
12 100.6 99.9 98.4 99.5 95.2 97.7 98.6±1.97
Remarks: comparison film is Clarinase , by the packing of Shanghai Schering Plough pharmaceutical Co. Ltd.Lot number: 01CJRPD002
Claims (2)
1. a slow releasing tablet that contains loratadine and pseudoephedrine sulfate is made up of immediate release section skin and slow-released part label, and wherein the immediate release section skin comprises loratadine and pseudoephedrine sulfate, and the slow-released part label is a pseudoephedrine sulfate.
It is characterized by:
A. the slow-released part label is formed:
The mg/ sheet
Pseudoephedrine sulfate 40-80
Glyceryl Behenate 94-186
Calcium sulfate 13-27
Latex liquid of polymethacrylic resin (30%) 6-14
Magnesium stearate 1.3-2.7
B. the outer field composition of immediate release section:
The mg/ sheet
Loratadine 5
Pseudoephedrine sulfate 40-80
Hypromellose E50-LV 56-104
Sucrose 11-19
Lactose 91-183
Magnesium stearate 1.5-3.5
Sheet core segment and coatings are partly separately granulated separately, and be standby.Adopt the pressed coated machine to carry out compressed tablets.
2. contain loratadine 5mg in the immediate release section skin described in the claim 1, pseudoephedrine sulfate 60mg, sulfur acid pseudoephedrine 60mg in the slow-released part label.
A. the slow-released part label is formed:
The mg/ sheet
Pseudoephedrine sulfate 60
Glyceryl Behenate 140
Calcium sulfate 20
Latex liquid of polymethacrylic resin (30%) 10
Magnesium stearate 2
B. the outer field composition of immediate release section:
The mg/ sheet
Loratadine 5
Pseudoephedrine sulfate 60
Hypromellose E50-LV 75
Sucrose 15
Lactose 137
Magnesium stearate 3
Sheet core segment and coatings are partly separately granulated separately, adopt the pressed coated machine to carry out compressed tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031094023A CN1535686A (en) | 2003-04-09 | 2003-04-09 | Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031094023A CN1535686A (en) | 2003-04-09 | 2003-04-09 | Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1535686A true CN1535686A (en) | 2004-10-13 |
Family
ID=34319319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031094023A Pending CN1535686A (en) | 2003-04-09 | 2003-04-09 | Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1535686A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101596157A (en) * | 2008-06-04 | 2009-12-09 | 北京科信必成医药科技发展有限公司 | The compound slow release preparation of a kind of pseudoephedrine, chlorphenamine and dextromethorphan |
| CN101596156B (en) * | 2008-06-04 | 2011-09-28 | 北京科信必成医药科技发展有限公司 | Compound sustained-release preparation for paracetamol and pseudoephedrine |
| CN102247368A (en) * | 2011-05-19 | 2011-11-23 | 安徽永生堂药业有限责任公司 | Compound acrivastine sustained release tablets, and preparation method thereof |
| CN102283849A (en) * | 2011-06-29 | 2011-12-21 | 北京阜康仁生物制药科技有限公司 | Medicinal composition containing azatadine |
| CN101015519B (en) * | 2007-02-27 | 2012-03-21 | 重庆医药工业研究院有限责任公司 | Loratadine oral compound medication composition |
-
2003
- 2003-04-09 CN CNA031094023A patent/CN1535686A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101015519B (en) * | 2007-02-27 | 2012-03-21 | 重庆医药工业研究院有限责任公司 | Loratadine oral compound medication composition |
| CN101596157A (en) * | 2008-06-04 | 2009-12-09 | 北京科信必成医药科技发展有限公司 | The compound slow release preparation of a kind of pseudoephedrine, chlorphenamine and dextromethorphan |
| CN101596156B (en) * | 2008-06-04 | 2011-09-28 | 北京科信必成医药科技发展有限公司 | Compound sustained-release preparation for paracetamol and pseudoephedrine |
| CN102247368A (en) * | 2011-05-19 | 2011-11-23 | 安徽永生堂药业有限责任公司 | Compound acrivastine sustained release tablets, and preparation method thereof |
| CN102283849A (en) * | 2011-06-29 | 2011-12-21 | 北京阜康仁生物制药科技有限公司 | Medicinal composition containing azatadine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101073563A (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
| CN1257422A (en) | Solid pharmaceutical preparation | |
| CN1198666A (en) | Chewable tablet | |
| CN1957928A (en) | Controlled release preparation of clinical treating medication, and fabricating method | |
| CN1535686A (en) | Slowly-released preparation containing loratadine and pseudoephedrine sulfate and its preparation method | |
| CN1839802A (en) | Ambroxol hydrochloride oral disintegrating tablet and preparation method thereof | |
| CN1559390A (en) | Oral disintegration tablets contg. p-acetaminophenol, and prepn. method therefor | |
| CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method | |
| CN1443535A (en) | Tegasevod maleate oral preparation and its preparation process-for curing intestinal irritability syndrome | |
| CN1270712C (en) | Felodipine controlled-release preparation | |
| CN1568992A (en) | Orally disintegrating tablet of loratadine and its preparation method | |
| CN1297263C (en) | Calcium gluconate oral disintegrating tablet and its preparation process | |
| CN1883480A (en) | A pharmaceutical composition containing rupatatine | |
| CN1228046C (en) | Fluctin slow release tablet | |
| CN1468094A (en) | Novel pharmaceutical composition containing epimeditine and pseudoephedrine | |
| CN1634014A (en) | Sodium ferulate oral disintegrating tablet and its preparation process | |
| CN1857228A (en) | Oral gatifloxacin disintegrant and its preparing process | |
| CN1528273A (en) | Analgesic tramadol hydrochloride oral disintegrating tablet and preparing method thereof | |
| CN1726916A (en) | Oral disintegration tablet for dropping blood sugar and preparation method | |
| CN1430953A (en) | Tablet disintegzated in mouth rapidly for preventing and curing vomit and preparing method | |
| CN1559388A (en) | Tramadol hydrochloride oral disintegration tablets, and prepn. method therefor | |
| CN1839847A (en) | Tizanidine hydrochloride orally disintegrating tablet and preparation method thereof | |
| CN1186668A (en) | Sinomenine hydrocloride preparation and its preparing process | |
| CN1562210A (en) | Burnet disintegration tablet of mouth and preparation method | |
| CN1429618A (en) | Erigeron breviscapus oral caving fast disintegration tablet and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |